Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 84Recurrence 10Lymphoma 8Leukemia, Myeloid, Acute 6Immunoglobulin Light-chain Amyloidosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Plasmacytoma 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Amyloidosis 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1

Interventions

Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5Cyclophosphamide 5Rituximab 4prednylidene 3deltacortene 3daratumumab 2Cytarabine 2varlilumab 1pomalidomide 1merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Vorinostat 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Hydrocortisone 1Disulfides 1Dexamethasone 1Carmustine 1CT-P10 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Plasmablastic Lymphoma × ixazomib × Clear all
NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡